YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023

Provided By PR Newswire

Last update: Apr 18, 2023

FY2023 Revenues Increased by Approximately 30% Year Over Year

GAITHERSBURG, Md., April 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its preliminary unaudited financial results for the fiscal year ended March 31, 2023 ("Fiscal Year 2023"):